# Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

> **NCT02343679** · PHASE2 · WITHDRAWN · sponsor: **Anne Beaven, MD**

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** ceritinib

## Key facts

- **NCT ID:** NCT02343679
- **Lead sponsor:** Anne Beaven, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-05
- **Primary completion:** 2020-10
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No accrual due to rarity of disease.
- **Last updated:** 2017-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343679, "Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02343679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*